Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 10 October 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) has released a mid-year report detailing its progress in 2012, showing a projected decline in the number of submitted applications even as products seeking orphan designations surged 30%.
The report, highlighted in an EMA press release on 10 October, was originally reported to EMA's management board by Executive Director Guido Rasi.
Rasi, who took over EMA this year after Thomas Lonngren stepped down in the midst of controversy, has been making a series of transparency overhauls aimed at making the EU regulator more accountable. The report seems targeted at similar objectives, and outlines where EMA has made progress relative to 2011, and where it has the potential to miss its targets.
"Our main performance indicators have been met," said Rasi. "The mid-year report indicates that the Agency is on target to meet its core business objectives for 2012."
However, the report cautions that EMA may not be on pace to meet its objective for much longer, though not necessarily because of any action taken by regulators. "The forecast for applications to be submitted by the end of the year has been reduced from 112 to 101, owing mainly to a lower rate of submission of applications for generic medicinal products for human use than expected," it explained. Through the first half of 2012, EMA said it approved approximately the same number of applications as 2011-52-but did not specify the exact number.
The report also highlighted that more companies seem to be submitting requests for scientific advice and protocol assistance, perhaps as a result of new guidance aimed at clarifying the process of doing so for sponsors. From 2011 to 2012, requests for scientific advice increased 14% and requests for protocol assistance increased by 24%, "Confirming the growing importance for pharmaceutical companies to seek early advice from the Agency on their medicines-development programs," explained EMA.
Tags: Drug Approvals, Rasi, Report, Approvals, Latest News, Orphan Drugs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.